Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of MB09 (Denosumab Biosimilar) vs Xgeva in Healthy Males
NCT05299073Phase 1Completed
- Sponsor
- mAbxience
- Start
- Mar 2022
- Primary completion
- Mar 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of DenOsteoRel in solid tumor (3 arms), sponsored by mAbxience. Primary endpoints: Area Under the Curve (AUC0-last) at Day 253 and Maximum Observed Serum Concentration (Cmax) at Day 253. Started Mar 2022; status: completed.
02
Drugs
DenOsteoRel
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05299073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05299073.